Because all the mechanisms suggested were not applicable in our resistant lines, we screened an ovarian cancer cell line (which is the most clinically applicable context for continuous PARP inhibitor therapy [4]) by RNA sequencing, and note increased NF-κB pathway activation. This evidence concerns the gene PARP1 and ovarian carcinoma.